The performance of Vertex Pharmaceuticals Inc.'s cystic fibrosis portfolio was strong coming out of 2017, and analysts' rave reviews about the potential for triple-therapy combinations the specialty pharma plans to bring into pivotal trials during 2018 spurred speculation of shutting other companies – namely the partnership of AbbVie Inc. and Galapagos NV – out of the CF market entirely.
Out of four next-generation cystic fibrosis transmembrane conductance regulator (CFTR) correctors Vertex moved into Phase II, VX-659 and VX-445 were chosen to continue into Phase III on the basis of top-line Phase II data unveiled Jan. 31
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?